Publication rates and reported results in a cohort of gene-and cell-based therapy trials

Research output: Contribution to journalJournal articleResearchpeer-review

  • Delphi G.M. Coppens
  • Helga Gardarsdottir
  • Cornelis A. Van Den Bogert
  • Marie L. De Bruin
  • Hubert G.M. Leufkens
  • Jarno Hoekman

Aim: We investigated publication rates and reported results for gene-and cell-based therapy trials. Materials & methods: In a cohort of Institutional Review Board (IRB)-authorized trials during 2007-2017 in the Netherlands (n = 105), we examine publication rates and reported results in scientific papers and conference abstracts as well as associations with the occurrence of trial characteristics. Results: The publication rate for scientific papers was 27% and 17% for conference abstracts (median survival time: 1050 days). Academic hospitals published more in scientific papers whereas private sponsors published more in conference abstracts. Manufacturing protocols were underreported compared with clinical outcomes. Most publications reported positive results (78%). Conclusion: Publication rates are currently suboptimal indicating a need for enhanced knowledge sharing to stimulate gene-and cell-based therapy development.

Original languageEnglish
JournalRegenerative Medicine
Volume15
Issue number1
Pages (from-to)1215-1227
Number of pages13
ISSN1746-0751
DOIs
Publication statusPublished - 2020

    Research areas

  • academic research, clinical trial cohort, clinical trial transparency, commercial development, conference abstract, drug regulatory science, gene-and cell-based therapies, publication bias, scientific publication

ID: 239635930